National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 49689-49690 [E8-19450]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices
Agenda: To discuss the training programs
of the Institute.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Stephen J. Korn, PhD,
Training and Special Programs Officer,
National Institute of Neurological Disorders
and Stroke, National Institutes of Health,
6001 Executive Blvd., Suite 2154, MSC 9527,
Bethesda, MD 20892–9527, (301) 496–4188.
Name of Committee: National Advisory
Neurological Disorders and Stroke Council,
Basic and Preclinical Programs
Subcommittee.
Date: September 18, 2008.
Time: 8 a.m. to 10 a.m.
Agenda: To discuss basic and preclinical
programs policy.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C Wing,
Conference Room 7, Bethesda, MD 20892.
Contact Person: Jill E. Heemskerk, PhD,
Acting Chief, Technology Development,
National Institute of Neurological Disorders
and Stroke, National Institutes of Health,
6001 Executive Boulevard, Suite 2229, MSC
9527, Bethesda, MD 20892–9527, (301) 496–
1779, jh440o@nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.ninds.nih.gov, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–19449 Filed 8–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jlentini on PROD1PC65 with NOTICES
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
President’s Cancer Panel.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
VerDate Aug<31>2005
17:12 Aug 21, 2008
Jkt 214001
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(9)(B), Title 5 U.S.C., as
amended, because the premature
disclosure of these discussions would
be likely to significantly frustrate
implementation of recommendations.
Name of Committee: President’s Cancer
Panel.
Date: September 16, 2008.
Open: September 16, 2008, 8 a.m.–4:15
p.m.
Agenda: Environmental Factors in Cancer.
Place: Hilton East Brunswick, 3 Tower
Center Boulevard, East Brunswick, NJ 08816.
Closed: September 16, 2008, 4:30 p.m.–
7:30 p.m.
Agenda: Discussion concerning the release
of the final report and recommendations from
the 2007–2008 series; discussion of
testimony given in open session on
Environmental Factors in Cancer;
consideration of thematic concepts for the
2009/2010 series.
Place: Hilton East Brunswick, 3 Tower
Center Boulevard, East Brunswick, NJ 08816.
Contact Person: Abby Sandler, Ph.D.,
Executive Secretary, National Cancer
Institute, National Institutes of Health,
Building 6116, Room 220, MSC 8349, 6116
Executive Boulevard, Bethesda, MD 20892,
301/451–9399.
Any interested person may file written
comments with the committee by forwarding
the comments to the Contact Person listed on
this notice. The comments should include
the name, address, telephone number and,
when applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/pcp/pcp.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–19448 Filed 8–21–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
49689
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors, NIDDK.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Diabetes and
Digestive and Kidney Diseases,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIDDK.
Date: October 6–7, 2008.
Time: October 6, 2008, 9 a.m. to 5 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 10, 10 Center Drive, 9S235,
Bethesda, MD 20892.
Time: October 7, 2008, 9 a.m. to 4 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 10, 10 Center Drive, 9S235,
Bethesda, MD 20892.
Contact Person: Ira W. Levin, PhD, Chief,
Section on Molecular Biophysics, Division of
Intramural Research, National Institute of
Diabetes and Digestive and Kidney Diseases,
NIH, Bethesda, MD 20892, 301–496–6844,
iwl@helix.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
E:\FR\FM\22AUN1.SGM
22AUN1
49690
Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–19450 Filed 8–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Workgroup Meeting; Notice
Is Hereby Given of a Meeting of the
Strategic Planning Implementation
Workgroup (SPIWG) Organized by the
Interagency Autism Coordinating
Committee (IACC)
jlentini on PROD1PC65 with NOTICES
The purpose of the workgroup
meeting is to discuss future budgetary
requirements for the IACC Strategic Plan
for Autism Spectrum Disorder (ASD)
Research. The workgroup findings will
be forwarded to the IACC for
consideration and discussion at the next
committee meeting on November 21,
2008.
Audio of this workgroup meeting will
be accessible to the public via a
teleconference phone link, and there
will be Web-based access to information
displayed at the meeting via computer/
projector. Attendance at the meeting
will be limited due to space available.
Name of Committee: Interagency Autism
Coordinating Committee (IACC).
Type of Meeting: Strategic Planning
Implementation Working Group.
Date: September 10, 2008.
Time: 11 a.m. to 3 p.m. EDT.
Agenda: To discuss future budgetary
requirements for the IACC Strategic Plan for
Autism Spectrum Disorder (ASD) Research.
Place: National Institutes of Health,
Building 1, Wilson Hall, Bethesda, MD
20892.
Access Information: Conference Call and
Webinar, Webinar Registration and Access
Information: https://www1.gotomeeting.com/
register/550445924. To Access the
Conference Call: Dial: Number: 888–455–
2920. Access Code: 3857872.
Contact Person: Azik Schwechter, Ph.D.,
Office of Autism Research Coordination,
Office of the Director, National Institute of
Mental Health, NIH, 6001 Executive
Boulevard, NSC Room 8203a, Bethesda, MD
20892–9669, 301–443–7163,
IACCPublicInquiries@mail.nih.gov.
Please Note: The workgroup meeting will
be open to the public through a conference
call phone number and a web presentation
tool on the Internet. Individuals who
participate using these electronic services
and who need special assistance, such as
captioning of the conference call or other
VerDate Aug<31>2005
17:12 Aug 21, 2008
Jkt 214001
reasonable accommodations, should submit a
request at least 2 weeks prior to the meeting.
Members of the public who participate
using the conference call phone number will
be able to listen to the meeting but will not
be heard. There may be an opportunity for
members of the public to submit written
comments during the workgroup meeting
through the web presentation tool. Submitted
comments will be reviewed after the meeting.
If you experience any technical problems
with the web presentation tool, please
contact GoToWebinar at (800) 263–6317. To
access the web presentation tool on the
Internet the following computer capabilities
are required:
A. Internet Explorer 5.0 or later, Netscape
Navigator 6.0 or later or Mozilla Firefox 1.0
or later;
B. Windows 2000, XP Home, XP Pro,
2003 Server or Vista;
C. Stable 56k, cable modem, ISDN, DSL or
better Internet connection;
D. Minimum of Pentium 400 with 256 MB
of RAM (Recommended);
E. Java Virtual Machine enabled
(Recommended).
Information about the IACC is available on
the Web site: https://www.nimh.nih.gov/
research-funding/scientific-meetings/
recurring-meetings/iacc/index.shtml.
Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–19455 Filed 8–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Diagnostics Based on
Immune Reactions to Brother of the
Regulator of Imprinted Sites (BORIS)
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
Department of Health and Human
Services is contemplating the grant of an
exclusive license to practice the
inventions embodied in PCT
Application No. PCT/US2007/77281,
entitled ‘‘BORIS Isoforms and Methods
of Detecting and Treating Disease’’ filed
August 30, 2007 (E–117–2006/0–PCT–
02); EP Application No. 05799643.1,
entitled ‘‘Method of Detecting Cancer
Based On Immune Reaction To BORIS’’
filed September 21, 2005 (E–241–2004/
0–EP–03); U.S. Application Serial No.
11/575,732, entitled ‘‘Method of
Detecting Cancer Based On Immune
Reaction To BORIS’’ filed March 21,
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
2007 (E–241–2004/0–US–04); U.S.
Patent No. 7,375,206, entitled ‘‘Brother
of The Regulator of Imprinted Sites
(BORIS)’’ issued May 28, 2008 (E–227–
2001/0–US–03); and EP Patent
Application No. 03743179.8, entitled
‘‘Brother of The Regulator of Imprinted
Sites (BORIS)’’ filed September 17, 2004
(E–227–2001/0–EP–04) to Wellstat
Diagnostics, Inc.
The prospective exclusive territory
may be worldwide, and the field of use
may be limited to manufacture and sale
of diagnostics for cancer and cancer
predisposition.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before October 21, 2008 will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: Mojdeh
Bahar, J.D., Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804. Telephone:
(301) 435–2950; Facsimile: (301) 402–
0220; E-mail: baharm@od.nih.gov.
SUPPLEMENTARY INFORMATION: The
above-mentioned patent applications
describe the human protein Brother of
Regulator of Imprinted Sites (‘‘BORIS’’),
and a method of detecting cancer by
monitoring BORIS expression or by
detecting anti-BORIS antibodies. Dr.
Victor V. Lobanenkov and colleagues at
the National Institute of Allergy and
Infectious Diseases discovered BORIS
and its potential application as a cancer
diagnostic. BORIS is a paralog of
CCCTC-binding factor (‘‘CTCF’’), a
transcription factor that also functions
in chromatin insulation. The amino acid
sequences of BORIS and CTCF contain
eleven conserved zinc fingers each of
which binds to DNA. BORIS protein can
be detected in cancer cells, and
importantly, it is one of a few cancertestis antigens that are immunogenic in
humans.
BORIS resides in 20q13.2, a region
that is commonly amplified in many
human cancers. Normally, BORIS
mRNA can be detected in testis, but not
in other human tissues. However,
BORIS mRNA is detectable in over one
hundred cancer cell lines representing
most of the major forms of human
tumors and is also detectable in primary
breast cancer tumor samples, but not in
controls. BORIS protein is misexpressed in cancer cell lines, and
antibodies against BORIS have been
detected in serum from patients with
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 73, Number 164 (Friday, August 22, 2008)]
[Notices]
[Pages 49689-49690]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-19450]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the Board of Scientific Counselors, NIDDK.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Diabetes and Digestive and Kidney Diseases, including
consideration of personnel qualifications and performance, and the
competence of individual investigators, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NIDDK.
Date: October 6-7, 2008.
Time: October 6, 2008, 9 a.m. to 5 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 10, 10 Center
Drive, 9S235, Bethesda, MD 20892.
Time: October 7, 2008, 9 a.m. to 4 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 10, 10 Center
Drive, 9S235, Bethesda, MD 20892.
Contact Person: Ira W. Levin, PhD, Chief, Section on Molecular
Biophysics, Division of Intramural Research, National Institute of
Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892,
301-496-6844, iwl@helix.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition
[[Page 49690]]
Research; 93.849, Kidney Diseases, Urology and Hematology Research,
National Institutes of Health, HHS)
Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-19450 Filed 8-21-08; 8:45 am]
BILLING CODE 4140-01-P
